Survodutide (BI 456906)

Survodutide lands at neutral because it pairs a genuinely exciting liver mechanism with an unfinished, investigational file and a grey-market-only supply. The practical read: if your main concern is serious fatty liver disease and you want the most direct hepatic action in the GLP-1 family, survodutide is the most interesting bet in the pipeline, with 62% biopsy-confirmed improvement on its best dose, per Sanyal 2024. But if your goal is weight loss, approved drugs already do more with a known supply chain. The neutral score reflects that balance: large effects and a unique mechanism on one side, no approval, topline-only Phase 3 data, a 20% dropout rate, and an unproven heart profile on the other.

✅ Best for: People focused on metabolic-associated fatty liver disease who value survodutide's direct glucagon-driven liver mechanism over a weight-only approach. Patients with significant weight to lose who also carry liver fat, where the dual benefit compounds. Type 2 diabetics interested in the combined glucose and weight effect shown against semaglutide, per Bluher 2024. Experimentally minded users who accept investigational status, can monitor liver enzymes, glucose, and heart rate, and will titrate slowly to manage nausea. Anyone willing to wait for the Phase 3 liver readout before drawing firm conclusions.

❌ Avoid if: You have a personal or family history of medullary thyroid cancer or MEN 2, matching the class warning, per Le Roux 2024. You have a baseline fast or irregular heartbeat, given the glucagon-driven heart-rate rise, per Dahl 2024. You have a history of pancreatitis, active gastrointestinal disease, or you are pregnant or breastfeeding. You want a proven, approved option, since survodutide is investigational with no cardiovascular outcome data. You cannot verify the identity and purity of grey-market material, because contaminated or mislabeled product can outweigh the drug's own risks.